Clinical trials
Prostate Cancer (Diagnosis) clinical trials
Below are recruiting prostate cancer (diagnosis) clinical trials, each written for real people, not researchers. We’re tracking 426 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT05956639RecruitingPhase 3
Rezvilutamide with ADT and chemo: shorter versus longer treatment
This Phase 3 trial compares two lengths of rezvilutamide treatment when given with hormone therapy (ADT) and chemotherapy for men with advanced prostate cancer. It aims to find which treatment duration works best and is safest to help control the cancer.
Nanjing, JiangsuAges 18 years+ - NCT06136624RecruitingPhase 3
Comparing a new drug to standard hormone therapy for advanced prostate cancer
This trial tests a new pill, opevesostat, against other hormone treatments for men with metastatic castration-resistant prostate cancer that has progressed after previous therapies. It aims to see which approach works better.
Orange, CaliforniaAges 18 years+ - NCT05649943Recruiting
New prostate cancer treatment plus local therapy for metastatic cases
This trial studies whether adding apalutamide to standard hormone therapy (ADT) improves outcomes for men with metastatic hormone-sensitive prostate cancer. Some people may also receive local treatments (like surgery or radiotherapy) to control the prostate and nearby areas.
Milan, LombardyAges 18 years+ - NCT06492122RecruitingPhase 1
Study of a radioactive drug for advanced prostate cancer
This trial tests a new radioactive treatment, [225Ac]Ac-FL-020, for men with metastatic castration-resistant prostate cancer (mCRPC) that has gotten worse despite other treatments. It's for those who have had at least one prior hormone therapy or chemotherapy.
Duarte, CaliforniaAges 18 years+ - NCT07514065RecruitingPhase 1
TSL2109 Safety and Effectiveness Study in Advanced Cancers
This early-stage study tests a new drug called TSL2109 in patients with advanced solid cancers that haven't responded to standard treatment. Researchers want to find the right dose, understand how the body processes it, and see if it can slow or shrink tumors, with special focus on certain prostate and breast cancers.
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT07162779Enrolling by invitation
New PET scan for advanced prostate cancer patients
This trial tests a new type of PET scan using a radioactive tracer called [68Ga]DOTA-IR-780-C-4 to see if it can find prostate cancer cells that express a protein called PSMA. If you have advanced prostate cancer that has stopped responding to standard treatments, this scan may help your doctor better understand your cancer and possibly guide future care.
Wuxi, JiangsuAges 18–80 - NCT05939414RecruitingPhase 3
Lutetium prostate cancer treatment for limited PSMA-spread
This Phase 3 trial compares a targeted radiation medicine called lutetium (177Lu) vipivotide tetraxetan versus watchful waiting in people with prostate cancer that has spread to only a few spots. The goal is to see if the treatment can better control the cancer when scans show a small amount of PSMA-positive metastases.
Fayetteville, ArkansasAges 18–100 - NCT05762536RecruitingPhase 2
Docetaxel or cabazitaxel with or without darolutamide
This Phase 2 study tests whether adding darolutamide to either docetaxel or cabazitaxel helps treat men with advanced, progressing prostate cancer. It’s for cancers that have already grown despite hormone-blocking tablets (ARSi).
RotterdamAges 18 years+ - NCT06943495RecruitingPhase 1
Personalized vs. standard dose of a targeted therapy for prostate cancer
This trial compares two ways of giving a radioactive drug (177Lu-PSMA-617) designed to find and destroy prostate cancer cells. It tests whether adjusting the dose based on your individual tumor’s activity works better than a fixed standard dose.
Québec, QuebecAges 18 years+ - NCT07300631Recruiting
SpaceOAR gel use during prostate cancer radiation
This study is a registry that collects information from people receiving standard care with a gel called SpaceOAR during radiation therapy for prostate cancer. It helps doctors learn more about how the gel works in routine practice.
BrestAges 18 years+ - NCT03067051RecruitingPhase 1/Phase 2
Test of a prostate cancer light-activated treatment device
This study tests the safety and early effectiveness of the SpectraCure P18 system, which uses light-activated medicine to treat prostate cancer that has come back locally after radiation. It may help some people avoid or delay more invasive treatment, while researchers carefully watch side effects.
New York, New YorkAges 18 years+ - NCT04100174RecruitingPhase 2
HDR radiation boost for prostate cancer during standard treatment
This study tests adding a targeted “boost” of HDR (high-dose-rate) internal radiation to the prostate along with standard external beam radiation. It may help improve cancer control while keeping the treatment focused on the area seen on scans and biopsy.
Montreal, QuebecAges Any age - NCT05761093Recruiting
Share your treatment preferences for metastatic prostate cancer
This study asks people with metastatic prostate cancer and their doctors about what benefits and risks matter most when choosing treatment. Your answers can help improve how treatment options are discussed in Hong Kong.
ShatinAges 18 years+ - NCT06039085Recruiting
Electrical sensing for real-time cancer margin check during prostate surgery
This study tests a new device that uses tiny electrical sensors to help surgeons check if all the cancer has been removed during prostate cancer surgery. It could give real-time feedback so the surgeon can remove leftover cancer right away.
Lebanon, New HampshireAges 18 years+ - NCT06084338RecruitingPhase 2
Focused Radiation Therapy Without Hormone Therapy for Advanced Prostate Cancer
This trial tests whether giving focused radiation to many cancer spots (SBRT) can work without using testosterone-blocking hormone therapy. It is for men whose prostate cancer has spread and is no longer responding to low testosterone, and who have already tried one of the newer hormone drugs.
West Los Angeles, CaliforniaAges 18 years+ - NCT06200558Recruiting
Study of treatments for advanced prostate cancer
This study looks back at the experiences of men with prostate cancer that has spread to other parts of the body. It aims to learn which treatments—such as hormone therapy combined with other drugs, or a radioactive therapy—work best for different types of advanced prostate cancer.
Province of Macerata, MacerataAges 18 years+ - NCT06262139RecruitingPhase 1/Phase 2
New MRI dye for high-risk prostate cancer
This trial tests a new MRI contrast dye that might help doctors see aggressive prostate cancer more clearly. It is for men with high-risk prostate cancer (Gleason 8-10) who have already had an MRI and a biopsy.
Atlanta, GeorgiaAges 18–90 - NCT06279260Recruiting
National robotic prostate surgery database study
This study collects health information from men who have had robotic surgery for prostate cancer. It aims to learn more about the outcomes of this surgery to help improve future care.
Ballarat, VictoriaAges 18–90 - NCT06303622Recruiting
Comparing two MRI-guided biopsy methods for prostate cancer
This trial compares two ways to guide a prostate biopsy using MRI images, to see which better detects clinically significant prostate cancer in men with suspicious MRI findings.
Hong KongAges 18 years+ - NCT06450106RecruitingPhase 1
STM-416p injection during prostate removal surgery
This trial tests an injection called STM-416p given during prostate removal surgery to see if it can help prevent prostate cancer from coming back. It may be an option for men with intermediate to high-risk prostate cancer who are already planning to have their prostate removed.
Tucson, ArizonaAges 18 years+ - NCT06496256Recruiting
Barrigel gel for radiation after prostate removal
This trial tests a gel placed in the rectum during radiation therapy to protect healthy tissue after prostate removal. It is for men whose prostate cancer has come back (PSA rise) and who need radiation to the prostate bed.
Boston, MassachusettsAges 18 years+ - NCT06496581RecruitingPhase 3
Adding a targeted radiation drug for prostate cancer that hasn't responded well to initial treatment
This trial tests if adding a radioactive drug called 177Lu-PSMA-617 to standard therapy helps men whose prostate cancer has spread and hasn't responded well to initial hormone therapy. It's for men whose PSA level is still detectable after 6-8 months of treatment.
AngersAges 18–80 - NCT06521710Recruiting
Nerve grafting to preserve erections after prostate removal
This trial tests if a nerve grafting technique can help preserve erectile function after robotic surgery for high-risk localized prostate cancer. It may be an option for men with good preoperative erectile function.
Montreal, QuebecAges 18 years+ - NCT06683066RecruitingPhase 1
Testing a prostate cancer drug for bioequivalence
This trial checks if a new version of the prostate cancer drug triprerelin works the same as the current one. It may be an option for men with prostate cancer who need hormone therapy.
Qingdao, ShandongAges 18 years+
Hear when a new Prostate Cancer (Diagnosis) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for prostate cancer (diagnosis)?
- Yes. Clin2 currently lists 426 recruiting prostate cancer (diagnosis) studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a prostate cancer (diagnosis) trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a prostate cancer (diagnosis) trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.